Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.

被引：5
|
作者：
Hofman, Michael
Violet, John A.
Hicks, Rodney J.
Ferdinandus, Justin
Thang, Sue Ping
Iravani, Amir
Kong, Grace
Kumar, Aravind Ravi
Akhurst, Timothy J.
Mooi, Jennifer
Guo, Christina
Tran, Ben
Jackson, Price
Scalzo, Mark
Eu, Peter
Williams, Scott
Sandhu, Shahneen Kaur
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Peter MacCallun Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.228
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
228
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.
    Sandhu, Shahneen Kaur
    Violet, John A.
    Ferdinandus, Justin
    Thang, Sue-Ping
    Iravani, Amir
    Guo, Christina
    Kong, Grace
    Kumar, Aravind Ravi
    Akhurst, Timothy J.
    Beaulieu, Alexis
    Murphy, Declan G.
    Mooi, Jennifer
    Tran, Ben
    Toner, Guy C.
    Williams, Scott
    Hicks, Rodney J.
    Hofman, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2020, 203 (05): : 882 - 882
  • [3] High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial
    Hofman, Michael
    Violet, John
    Sandhu, Shahneen
    Ferdinandus, Justin
    Thang, Sue Ping
    Iravani, Amir
    Kong, Grace
    Kumar, Aravind Ravi
    Akhurst, Tim
    Jackson, Price
    Scalzo, Mark
    Williams, Scott
    Hicks, Rodney
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [4] Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
    Hofman, M. S.
    Sandhu, S.
    Eu, P.
    Price, J.
    Akhurst, T.
    Iravani, A.
    Kong, G.
    Ravi-Kumar, A.
    Williams, S.
    Thang, S-P.
    Murphy, D.
    Scalzo, M.
    Hicks, R. J.
    Violet, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
    Ranjan, Satish Kumar
    INDIAN JOURNAL OF UROLOGY, 2020, 36 (03) : 227 - 228
  • [6] Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review
    Patell, Kanchi
    Kurian, Matthew
    Garcia, Jorge A.
    Mendiratta, Prateek
    Barata, Pedro C.
    Jia, Angela Y.
    Spratt, Daniel E.
    Brown, Jason R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (07) : 731 - 744
  • [7] Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer.
    Gonzalez, Brian D.
    Brownstein, Naomi C.
    Fan, Wenyi
    Dicker, Adam P.
    Oswald, Laura B.
    Dhillon, Haryana M.
    Jim, Heather S. L.
    Sandhu, Shahneen Kaur
    Tagawa, Scott T.
    Williams, Scott
    Hofman, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [8] RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.
    Calais, Jeremie
    Fendler, Wolfgang P.
    Eiber, Matthias
    Lassmann, MIchael
    Dahlbom, Magnus
    Esfandiari, Rouzbeh
    Gartmann, Jeannine
    Nguyen, Kathleen
    Pan Thin
    Lok, Vincent
    Herrmann, Ken
    Czernin, Johannes
    Delpassand, Ebrahim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Real-world treatment patterns with lutetium-177-PSMA-617 (177-Lu-PSMA) in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Dwabe, Sami
    Yazdanpanah, Omid
    Warnecke, Brian
    Benjamin, David Joseph
    Rezazadeh, Arash
    Mar, Nataliya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
    Gaudreault, Mathieu
    Chang, David
    Hardcastle, Nicholas
    Jackson, Price
    Kron, Tomas
    Hofman, Michael S.
    Siva, Shankar
    FRONTIERS IN ONCOLOGY, 2023, 13
12345